SFSean Michael Fortier

Sean Michael Fortier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sean Michael Fortier has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endogenous cAMP production within tissue fibroblasts is required for spontaneous fibrosis resolution

    by Sean M. Fortier, Jennifer Speth, Natalie M. Walker, Jared D. Baas, Kevin Wang, Vivian T. Wong, Steve D. Guzman, Yang Liu, Haichun Pan, Hao Ren, et al.

    Pathologic myofibroblasts (MFs) are pivotal effector cells in the development of persistent tissue fibrosis following parenchymal injury, and their activation and accumulation has been linked to a failure to phenotypically dedifferentiate and thus to resist apoptosis. The second messenger cyclic AMP (cAMP) has been shown to induce MF dedifferentiation and restore their sensitivity to apoptosis in vitro, but its endogenous role within MFs during fibrosis resolution in vivo has not been explored. To test the hypothesis that cAMP generation and signaling within fibroblasts is essential for fibrosis resolution, we leveraged the spontaneously resolving nature of the single-dose intrapulmonary and subcutaneous bleomycin models in mice with an inducible and fibroblast-specific abrogation of cAMP generation owing to deletion of the stimulatory G protein (Gαs). Abolishing cAMP generation in fibroblasts after peak lung fibrosis was established led to a failure of the resolution with single-cell RNA seq demonstrating conspicuous differences in pathway enrichment and cellular cross-talk not only in fibroblasts, but also within macrophages and epithelial cells. Spontaneous resolution of skin fibrosis in a model of scleroderma similarly required cAMP production in dermal fibroblasts. We conclude that cAMP generation within fibroblasts after tissue fibrosis has been established is required for its spontaneous resolution in the lung and skin. Our findings provide new insights into factors governing the outcome of tissue fibrosis as well as a mechanistic basis that helps to explain the therapeutic efficacy and ultimate potential of newly available and emerging cAMP-elevating agents.

  • Open Access

    Longitudinal single-cell RNA-seq profiling of lung cell phenotypes, signaling, and cross-talk during fibrosis resolution

    by Jennifer Speth, Vivian T. Wong, Steve D. Guzman, Natalie M. Walker, Yang Liu, Rachel L. Zemans, Timothy S. Blackwell, Carlos A. Aguilar, Marc Peters-Golden, Sean M. Fortier

  • Open Access

    Longitudinal Single-Cell RNA-seq Profiling of Lung Cell Phenotypes, Signaling, and Cross-talk During Fibrosis Resolution

    by Jennifer Speth, Vivian T. Wong, Steve D. Guzman, Yang Liu, Natalie M. Walker, Rachel L. Zemans, Timothy S. Blackwell, Carlos A. Aguilar, Marc Peters-Golden, Sean M. Fortier

    Resolution of fibrosis following lung injury is distinguished from persistent/progressive parenchymal scarring through the timely clearance of aberrant cell types, removal of excess collagens, and regeneration of alveolar structure. The requisite signaling pathways, cellular cross-talk, and phenotypic shifts associated with, and required for, resolution of established lung fibrosis have not been well characterized. To address this critical knowledge gap, we performed longitudinal single-cell RNA sequencing of whole mouse lung digests obtained during spontaneously resolving fibrosis. We observed a putatively pro-fibrotic macrophage population emerge during peak fibrosis and undergo partial clearance during resolution. Our study also revealed conspicuous shifts in well-established pathways associated with tissue repair and fibrosis among immune, mesenchymal, and epithelial cells during spontaneous resolution. In addition to a decline in pro-fibrotic driver pathways, the putative anti-fibrotic pathways cAMP, HGF/MET, and TWEAK were enriched in several cell types during spontaneous resolution. CellChat analysis was used to predict the cellular senders and recipients of each pathway and characterize their longitudinal changes. Our characterization of the cellular and molecular dynamics in whole lungs during spontaneous fibrosis resolution provides a foundation for the identification of endogenous pathways that might be leveraged to treat pulmonary fibrosis.

  • Morphological reprogramming of primary cilia length mitigates the fibrotic phenotype in fibroblasts across diverse fibrotic conditions

    by Priyanka Verma, Bharat Yalavarthi, Swati Bhattacharyya, Dinesh Khanna, Johann E. Gudjonsson, Lam C. Tsoi, Rebecca Wells, Rebecca L. Ross, Natalia Riobo-Del Galdo, Francesco Del Galdo, et al.

    Myofibroblast differentiation, which occurs across fibrotic diseases, is marked by actin polymerization and assembly of α-smooth muscle actin (αSMA) stress fibers. Primary cilia (PC) are solitary membrane-bound organelles present on the majority of cells. PC length regulation is a complex process influenced by actin polymerization. We discovered that fibroblasts from diverse fibrotic conditions display significantly reduced PC length ex vivo. Treatment of healthy fibroblasts (non-fibrotic) with profibrotic TGF-β1 induced PC shortening, whereas silencing ACTA2 in systemic sclerosis (SSc) skin fibroblasts caused PC elongation. Importantly, we found that PC length was negatively correlated with αSMA levels in TGF-β1-treated healthy fibroblasts and pharmacologically dedifferentiated myofibroblasts. Our results suggest that during the fibrotic response, higher-order actin polymerization, along with microtubule destabilization by tubulin deacetylation, drives PC length shortening. In contrast, PC length elongation via stabilization of microtubule polymerization mitigates the fibrotic phenotype in fibrotic fibroblasts. These results reveal a potential link between PC length and fibroblast activation conserved across multiple fibrotic conditions. Our observations suggest that modulation of PC length might represent a novel therapeutic strategy for SSc and other treatment-resistant diseases associated with fibrosis.


  • Open Access

    Distinct cAMP Regulation in Scleroderma Lung and Skin Myofibroblasts Governs Their Dedifferentiation via p38α Inhibition

    by Jared D. Baas, John Varga, Carol Feghali‐Bostwick, Marc Peters‐Golden, Sean M. Fortier

    Fibrosis in systemic sclerosis/scleroderma (SSc) is characterized by the progressive accumulation and persistence in multiple organs of pathologic fibroblasts whose contractile properties and exuberant secretion of collagens promote tissue stiffness and scarring. Identifying a tractable mechanism for inactivating and possibly clearing these ultimate effector cells of progressive fibrosis, conventionally termed myofibroblasts (MFs), represents an appealing therapeutic strategy for patients with SSc. This can be accomplished by their phenotypic dedifferentiation, a process known to be promoted by the generation of the intracellular second messenger cyclic AMP (cAMP). Notably, however, the abilities of SSc fibroblasts derived from different tissues to generate cAMP—and dedifferentiate in response to it—have never been directly characterized or compared. Here we compared these two processes in lung and skin MFs derived from patients with SSc. While directly increasing intracellular cAMP induced comparable dedifferentiation of lung and skin SSc MFs, dedifferentiation in response to the well‐recognized cAMP stimulus prostaglandin E 2 (PGE 2 ) was diminished or absent in MFs from skin as compared to lung, in part due to differences in the expression of its target G protein‐coupled receptors (GPCRs). Importantly, treatment with a phosphodiesterase 4 inhibitor rescued the dedifferentiating effects of PGE 2 in skin SSc MFs. Finally, both cAMP‐mediated and direct pharmacologic inhibition of the MAPK p38α promoted dedifferentiation of lung and skin SSc MFs. We conclude that activation of the cAMP pathway and its subsequent inhibition of p38α dedifferentiates SSc MFs from both lung and skin, and may thus represent a therapeutic strategy to alleviate multi‐organ fibrosis in SSc.


  • Open Access

    Distinct cAMP regulation in scleroderma lung and skin myofibroblasts governs their dedifferentiation via p38α inhibition

    by Jared D. Baas, John Varga, Carol Feghali-Bostwick, Marc Peters-Golden, Sean Michael Fortier

    Fibrosis in systemic sclerosis/scleroderma (SSc) is characterized by the progressive accumulation and persistence in multiple organs of pathologic fibroblasts whose contractile properties and exuberant secretion of collagens promote tissue stiffness and scarring. Identifying a tractable mechanism for inactivating and possibly clearing these ultimate effector cells of fibrosis, conventionally termed myofibroblasts (MFs), represents an appealing therapeutic strategy for patients with SSc. This can be accomplished by their phenotypic dedifferentiation, a process known to be promoted by generation of the intracellular second messenger cyclic AMP (cAMP). Notably, however, the abilities of SSc fibroblasts derived from different tissues to generate cAMP – and dedifferentiate in response to it – have never been directly characterized or compared. Here we compared these two processes in lung and skin MFs derived from patients with SSc. While directly increasing intracellular cAMP induced comparable dedifferentiation of lung and skin SSc MFs, dedifferentiation in response to the well-recognized cAMP stimulus prostaglandin E 2 (PGE 2 ) was diminished or absent in MFs from skin as compared to lung, in part due to differences in the expression of its target G protein-coupled receptors (GPCRs). Importantly, treatment with a phosphodiesterase 4 inhibitor rescued the dedifferentiating effects of PGE 2 in skin SSc MFs. Finally, both cAMP-mediated and direct pharmacologic inhibition of the MAPK p38α promoted dedifferentiation of lung and skin SSc MFs. We conclude that activation of the cAMP pathway and its subsequent inhibition of p38α dedifferentiates SSc MFs from both lung and skin, and may thus represent a therapeutic strategy to alleviate multi-organ fibrosis in SSc.

  • Open Access

    MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution

    by Sean M. Fortier, Natalie M. Walker, Loka R. Penke, Jared D. Baas, Qinxue Shen, Jennifer M. Speth, Steven K. Huang, Rachel L. Zemans, Anton M. Bennett, Marc Peters-Golden

    Fibrosis following tissue injury is distinguished from normal repair by the accumulation of pathogenic and apoptosis-resistant myofibroblasts (MFs), which arise primarily by differentiation from resident fibroblasts. Endogenous molecular brakes that promote MF dedifferentiation and clearance during spontaneous resolution of experimental lung fibrosis may provide insights that could inform and improve the treatment of progressive pulmonary fibrosis in patients. MAPK phosphatase 1 (MKP1) influences the cellular phenotype and fate through precise and timely regulation of MAPK activity within various cell types and tissues, yet its role in lung fibroblasts and pulmonary fibrosis has not been explored. Using gain- and loss-of-function studies, we found that MKP1 promoted lung MF dedifferentiation and restored the sensitivity of these cells to apoptosis — effects determined to be mainly dependent on MKP1’s dephosphorylation of p38α MAPK (p38α). Fibroblast-specific deletion of MKP1 following peak bleomycin-induced lung fibrosis largely abrogated its subsequent spontaneous resolution. Such resolution was restored by treating these transgenic mice with the p38α inhibitor VX-702. We conclude that MKP1 is a critical antifibrotic brake whose inhibition of pathogenic p38α in lung fibroblasts is necessary for fibrosis resolution following lung injury.


  • Open Access

    KLF4 is a therapeutically tractable brake on fibroblast activation that promotes resolution of pulmonary fibrosis

    by Loka R. Penke, Jennifer M. Speth, Steven K. Huang, Sean M. Fortier, Jared Baas, Marc Peters-Golden

    There is a paucity of information about potential molecular brakes on the activation of fibroblasts that drive tissue fibrosis. The transcription factor Krüppel-like factor 4 (KLF4) is best known as a determinant of cell stemness and a tumor suppressor. We found that its expression was diminished in fibroblasts from fibrotic lung. Gain- and loss-of-function studies showed that KLF4 inhibited fibroblast proliferation, collagen synthesis, and differentiation to myofibroblasts, while restoring their sensitivity to apoptosis. Conditional deletion of KLF4 from fibroblasts potentiated the peak degree of pulmonary fibrosis and abrogated the subsequent spontaneous resolution in a model of transient fibrosis. A small molecule inducer of KLF4 was able to restore its expression in fibrotic fibroblasts and elicit resolution in an experimental model characterized by more clinically relevant persistent pulmonary fibrosis. These data identify KLF4 as a pivotal brake on fibroblast activation whose induction represents a therapeutic approach in fibrosis of the lung and perhaps other organs.